Department of Orthopaedic Surgery, Sir Charles Gairdner Hospital, Perth, WA, Australia.
Royal Perth Hospital, Perth, WA, Australia.
Eur J Orthop Surg Traumatol. 2023 May;33(4):709-738. doi: 10.1007/s00590-022-03241-y. Epub 2022 Mar 17.
The ideal route of tranexamic acid (TXA) administration in total hip arthroplasty (THA) or total knee arthroplasty (TKA) remains controversial. This study aims to identify the optima route of TXA administration in THA or TKA.
PUBMED, EMBASE, MEDLINE and CENTRAL database were systematically searched until 4 August 2021 for randomised studies that compared intravenous (IV) or intra-articular (IA) administration of TXA in THA or TKA.
Sixty-seven studies enrolling 8335 patients (IA: 4162; IV: 4173) were eligible for quantitative and qualitative analysis. Comparable results were demonstrated in the incidence of venous thromboembolisation (OR:0.96, p = 0.84), total blood loss (MD: - 9.05, p = 0.36), drain output (MD: - 7.36, p = 0.54), hidden blood loss (MD: - 6.85, p = 0.47), postoperative haemoglobin level (MD: 0.01, p = 0.91), haemoglobin drop (MD: - 0.10, p = 0.22), blood transfusion rate (OR: 0.99, p = 0.87), total adverse events (OR: 1.12, p = 0.28), postoperative range of motion (MD: 1.08, p = 0.36), postoperative VAS pain score (MD: 0.13, p = 0.24) and postoperative D-dimer level (MD: 0.61, p = 0.64). IV route of TXA administration was associated with significantly longer length of hospital stay compared to IA route of administration (MD: - 0.22, p = 0.01).
In this meta-analysis, both IV and IA route of TXA administration were equally effective in managing blood loss and postoperative outcomes in lower limb joints arthroplasty.
Level 1. PROSPERO Registration CRD42021271355.
氨甲环酸(TXA)在全髋关节置换术(THA)或全膝关节置换术(TKA)中的理想给药途径仍存在争议。本研究旨在确定 TXA 在 THA 或 TKA 中的最佳给药途径。
系统检索 PUBMED、EMBASE、MEDLINE 和 CENTRAL 数据库,直到 2021 年 8 月 4 日,以比较 TXA 静脉内(IV)或关节内(IA)给药在 THA 或 TKA 中的随机研究。
67 项研究共纳入 8335 例患者(IA:4162;IV:4173),符合定量和定性分析的条件。静脉血栓栓塞(OR:0.96,p=0.84)、总失血量(MD:-9.05,p=0.36)、引流量(MD:-7.36,p=0.54)、隐性失血量(MD:-6.85,p=0.47)、术后血红蛋白水平(MD:0.01,p=0.91)、血红蛋白下降(MD:-0.10,p=0.22)、输血率(OR:0.99,p=0.87)、总不良事件(OR:1.12,p=0.28)、术后活动范围(MD:1.08,p=0.36)、术后 VAS 疼痛评分(MD:0.13,p=0.24)和术后 D-二聚体水平(MD:0.61,p=0.64)方面,两组间无显著差异。与 IA 给药途径相比,IV TXA 给药途径的住院时间明显延长(MD:-0.22,p=0.01)。
在这项荟萃分析中,IA 和 IV 两种 TXA 给药途径在管理下肢关节置换术后失血和术后结果方面同样有效。
1 级。PROSPERO 注册 CRD42021271355。